Integrated Filing — IndAS



General information about company
Scrip Code 542920
NSE Symbol SUMICHEM
MSEI Symbol NOTLISTED
ISIN INE258G01013
Name of company SUMITOMO CHEMICAL INDIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 26-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment AGROCHEMICALS
Start date and time of board meeting 26-May-2025   15:56:00
End date and time of board meeting 26-May-2025   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-05-26
Indicate Company website link for updated RPT policy of the Company https://sumichem.co.in/investors-relations.php#Governance
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default on loans and debt securities.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 6648020000 30903690000
Other income 313550000 1194240000
Total income 6961570000 32097930000
2 Expenses
(a) Cost of materials consumed 4159760000 15738710000
(b) Purchases of stock-in-trade 733630000 3156650000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -859540000 -480820000
(d) Employee benefit expense 600120000 2459650000
(e) Finance costs 13840000 48680000
(f) Depreciation, depletion and amortisation expense 156090000 632610000
(f) Other Expenses
1 Other Expenses 840940000 3802560000
Total other expenses 840940000 3802560000
Total expenses 5644840000 25358040000
3 Total profit before exceptional items and tax 1316730000 6739890000
4 Exceptional items 0 0
5 Total profit before tax 1316730000 6739890000
6 Tax expense
7 Current tax 307400000 1684930000
8 Deferred tax 25260000 35480000
9 Total tax expenses 332660000 1720410000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 984070000 5019480000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 984070000 5019480000
17 Other comprehensive income net of taxes 2640000 -6590000
18 Total Comprehensive Income for the period 986710000 5012890000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4991460000 4991460000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.97 10.06
Diluted earnings (loss) per share from continuing operations 1.97 10.06
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.97 10.06
Diluted earnings (loss) per share from continuing and discontinued operations 1.97 10.06
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 4203080000
Capital work-in-progress 93570000
Investment property 0
Goodwill 0
Other intangible assets 0
Intangible assets under development 191330000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 1457850000
Trade receivables, non-current 0
Loans, non-current 1752060000
Other non-current financial assets 707370000
Total non-current financial assets 3917280000
Deferred tax assets (net) 0
Other non-current assets 1044390000
Total non-current assets 9449650000
2 Current assets
Inventories 6982770000
Current financial asset
Current investments 4548140000
Trade receivables, current 7631580000
Cash and cash equivalents 343420000
Bank balance other than cash and cash equivalents 15070000
Loans, current 1018800000
Other current financial assets 8144820000
Total current financial assets 21701830000
Current tax assets (net) 0
Other current assets 1163220000
Total current assets 29847820000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 39297470000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4991460000
Other equity 23974690000
Total equity attributable to owners of parent 28966150000
Non controlling interest
Total equity 28966150000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 860290000
Total non-current financial liabilities 860290000
Provisions, non-current 0
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 860290000
Current liabilities
Current financial liabilities
Borrowings, current 177620000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 313810000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4562980000
Total Trade payable 4876790000
Other current financial liabilities 3659880000
Total current financial liabilities 8714290000
Other current liabilities 616220000
Provisions, current 86000000
Current tax liabilities (Net) 54520000
Deferred government grants, Current 0
Total current liabilities 9471030000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 10331320000
Total equity and liabilites 39297470000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit and loss 3530000 -8800000
Total Amount of items that will not be reclassified to profit and loss 3530000 -8800000
2 Income tax relating to items that will not be reclassified to profit or loss 890000 -2210000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 2640000 -6590000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 6739890000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 48680000
Adjustments for decrease (increase) in inventories -933700000
Adjustments for decrease (increase) in trade receivables, current -580640000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -158430000
Adjustments for decrease (increase) in other non-current assets -28370000
Adjustments for other financial assets, non-current -642780000
Adjustments for other financial assets, current 758420000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 596960000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 113160000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 632610000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current -9690000
Adjustments for provisions, non-current 66470000
Adjustments for other financial liabilities, current 793810000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -7200000
Adjustments for dividend income 10000
Adjustments for interest income 817070000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) -202770000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -142040000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -512590000
Net cash flows from (used in) operations 6227300000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 1638110000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 4589190000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 8640000
Purchase of property, plant and equipment 280370000
Proceeds from sales of investment property 14454870000
Purchase of investment property 18866610000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 10000
Interest received 644050000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -4039410000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 173150000
Dividends paid 440280000
Interest paid 37660000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -11020000
Net cash flows from (used in) financing activities -662110000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -112330000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -112330000
Cash and cash equivalents cash flow statement at beginning of period 455750000
Cash and cash equivalents cash flow statement at end of period 343420000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & CO. LLP Yes 31-Jul-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Sumitomo Chemical India Limited Sumitomo Chemical Company, Limited Holding Company Sale of goods or services 9500000000 Approved 613880000 1279490000 1219240000
2 Sumitomo Chemical India Limited Sumitomo Chemical Asia Pte Limited Fellow Subsidiary Sale of goods or services 4440000 Approved 2170000 0 2170000
3 Sumitomo Chemical India Limited Sumitomo Chemical Agro Europe S.A.S. Fellow Subsidiary Sale of goods or services 75690000 Approved 15310000 34840000 15310000
4 Sumitomo Chemical India Limited Sumitomo Chemical Argentina SA Fellow Subsidiary Sale of goods or services 172640000 Approved 0 154040000 130880000
5 Sumitomo Chemical India Limited Sumitomo Chemical Brazil Industria Quimika S A Fellow Subsidiary Sale of goods or services 2535390000 Approved 945010000 1027330000 909830000
6 Sumitomo Chemical India Limited Sumitomo Chemical Company, Limited Holding Company Purchase of goods or services 9500000000 Approved 1830500000 1279490000 1219240000
7 Sumitomo Chemical India Limited Valent BioSciences LLC Fellow Subsidiary Purchase of goods or services 1207140000 Approved 494680000 227610000 461030000
8 Sumitomo Chemical India Limited Barrix Agro Sciences Private Ltd. Subsidiary Company Purchase of goods or services Approved 1400000 0 480000
9 Sumitomo Chemical India Limited Sumitomo Chemical Brazil Industria Quimika S A Fellow Subsidiary Purchase of goods or services 11130000 Approved 5650000 1027330000 909830000
10 Sumitomo Chemical India Limited Kanga & Company Enterprises controlled by key management personnel and their relatives: Purchase of goods or services 1000000 Approved 170000 0 0
11 Sumitomo Chemical India Limited Sumitomo Chemical Company, Limited Holding Company Any other transaction Miscellaneous Income 9500000000 Approved 5400000 1279490000 1219240000
12 Sumitomo Chemical India Limited Valent BioSciences LLC Fellow Subsidiary Any other transaction Miscelleneous Income 1390000 Approved 1390000 227610000 461030000
13 Sumitomo Chemical India Limited Sumitomo Chemical Company, Limited Holding Company Any other transaction Reimbursement of Expenses by Holding Company 9500000000 Approved 11050000 1279490000 1219240000
14 Sumitomo Chemical India Limited Valent BioSciences LLC Fellow Subsidiary Any other transaction Reimbursement of Expenses to fellow subsidiary 1510000 Approved 1510000 227610000 461030000
15 Sumitomo Chemical India Limited Sumitomo Chemical Agro Europe S.A.S. Fellow Subsidiary Any other transaction Reimbursement of Expenses by fellow subsidiary 220000 Approved 220000 34840000 15310000
16 Sumitomo Chemical India Limited Barrix Agro Sciences Private Ltd. Subsidiary Company Any other transaction Reimbursement of Expenses to subsidiary 50000 Approved 50000 0 480000
17 Sumitomo Chemical India Limited Sumitomo Chemical Australia Pty Ltd. Fellow Subsidiary Any other transaction Commission paid to fellow subsidiary 250000 Approved 250000 0 250000
18 Sumitomo Chemical India Limited Sumitomo Chemical Philippines, INC Fellow Subsidiary Any other transaction Commission paid to fellow subsidiary 210000 Approved 100000 110000 210000
19 Sumitomo Chemical India Limited Sumitomo Chemical India Superannuation Trust Post Employment Benefit Plans entity Any other transaction Post Employment Benefit Plans 10350000 Approved 10350000 0 0
20 Sumitomo Chemical India Limited Sumitomo Chemical India Gratuity Trust Post Employment Benefit Plans entity Any other transaction Post Employment Benefit Plans 79190000 Approved 79190000 1160000 3840000
21 Sumitomo Chemical India Limited Agrocel Industries Private Limited Enterprises controlled by key management personnel and their relatives: Purchase of goods or services 494540000 Approved 90750000 710000 240000
22 Sumitomo Chemical India Limited Agrocel Industries Private Limited Enterprises controlled by key management personnel and their relatives: Sale of goods or services 290000 Approved 290000 710000 240000
23 Sumitomo Chemical India Limited Mr. Lokesh Makam Managing Director of Subsidiary Remuneration 4810000 Approved 4810000 0 0
24 Sumitomo Chemical India Limited Mrs. Manasa Makam Relative of Managing Director of Subsidiary Remuneration 1510000 Approved 1510000 0 0
Total value of transaction during the reporting period 4115640000